Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The World Congresses on Controversies in Multiple Myeloma (COMy) Multiple Myeloma Highlights 2017 meeting is a post-IMW summary congress to be held in Paris, France on April 21-22, 2017.

The congress will offer the opportunity to discuss the latest information in the field of multiple myeloma and the data presented during the IMW17.

COMy 2017

21–22 April 2017 | Paris, France

COMy 2017

21–22 April 2017 | Paris, France

The World Congresses on Controversies in Multiple Myeloma (COMy) Multiple Myeloma Highlights 2017 meeting is a post-IMW summary congress to be held in Paris, France on April 21-22, 2017.

The congress will offer the opportunity to discuss the latest information in the field of multiple myeloma and the data presented during the IMW17.

Exciting new treatments in myeloma 5:13
Exciting new treatments in myeloma
Xavier Leleu • 21 Apr 2017
The IFM 2012-03 trial: what will the next step be? 2:42
The IFM 2012-03 trial: what will the next step be?
Xavier Leleu • 21 Apr 2017
Pros and cons of increasing CD38 expression 1:49
Pros and cons of increasing CD38 expression
Torben Plesner • 21 Apr 2017
Daratumumab: no evidence of disease after treatment? 1:05
Daratumumab: no evidence of disease after treatment?
Torben Plesner • 21 Apr 2017
PDL1 and CD38 antigen expression in NSCLC 3:03
PDL1 and CD38 antigen expression in NSCLC
Torben Plesner • 21 Apr 2017
Case study: daratumumab in a relapsed patient 3:27
Case study: daratumumab in a relapsed patient
Saad Usmani • 21 Apr 2017
How effective are monoclonal antibodies at improving overall survival? 3:34
How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau • 21 Apr 2017
Current standard of care for patients who are eligible for autologous stem cell transplantation 2:50
Current standard of care for patients who are eligible for autologous stem cell transplantation
Michele Cavo • 21 Apr 2017
Promising new combinations in the treatment of myeloma 1:57
Promising new combinations in the treatment of myeloma
Evangelos Terpos • 21 Apr 2017
Key findings of the Endeavour study 0:45
Key findings of the Endeavour study
Evangelos Terpos • 21 Apr 2017
The risk of skeletal adverse events with zoledronic acid 5:23
The risk of skeletal adverse events with zoledronic acid
Heinz Ludwig • 21 Apr 2017
Effective antibody therapy and updates from the POLLUX and CASTOR trials 1:56
Effective antibody therapy and updates from the POLLUX and CASTOR trials
Meletios Dimopoulos • 21 Apr 2017
How effective are current drug treatments for patients with myeloma kidney disease? 1:31
How effective are current drug treatments for patients with myeloma kidney disease?
Meletios Dimopoulos • 21 Apr 2017
Highlights on interesting data presented at COMy 2017 1:21
Highlights on interesting data presented at COMy 2017
Meletios Dimopoulos • 21 Apr 2017
Conflicting results of the EMN02 and staMINA trials 4:59
Conflicting results of the EMN02 and staMINA trials
Michele Cavo • 21 Apr 2017
What is induction therapy for autologous stem cell transplanation? 1:03
What is induction therapy for autologous stem cell transplanation?
Michele Cavo • 21 Apr 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals